Lundbeckfonden uddeler årligt over 500 mio. kr. til danskbaseret, sundhedsvidenskabelig forskning primært med fokus på hjernen.
Mentions in press and media 11
| Date | Title | Description |
| 03.07.2024 | Quantum Computing Startup Kvantify Secures €10 Million to Revolutionize Life Science Sector | In a significant development, Copenhagen-based quantum software start-up, Kvantify, has successfully closed a €10 million seed round to propel the advancement of quantum computing in the life science sector. The funding, spearheaded by Dani... |
| 03.07.2024 | Copenhagen-based Kvantify secures €10 million to unlock quantum computing for the life science sector | Kvantify, a leading quantum software start-up, has announced the successful closure of a €10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on ... |
| 03.07.2024 | Kvantify secures €10M Seed funding for quantum computing powered drug discovery | Danish Quantum software startup Kvantify, has announced the successful closure of a €10 million Seed round. Kvantify leverages quantum and high-performance computing to create revolutionising solutions for complex scientific and industrial ... |
| 25.09.2023 | Notify Therapeutics secures €5M to develop novel hormone-free fertility treatment for women | Read this article in: Copenhagen-based Notify Therapeutics, a “first-in-class” female fertility treatment, announced that it has secured €5M in a fresh round of funding. Notify Therapeutics, an initiative stemming from Professor Karin Lykke... |
| 05.05.2021 | Cytoki Pharma cierra una ronda de €38M liderada por Lundbeckfonden Emerge junto con Ysios Capital, Seventure Partners y +ND Capital | 05/05/2021 Nota de prensa YSIOS CAPITAL INVIERTE EN CYTOKI PHARMA. − La compañía biotecnológica Cytoki Pharma (Copenhague, Dinamarca) desarrolla nuevas proteínas basadas en interleuquina 22 (IL-22) para el tratamiento de lesiones epiteli... |
| 05.05.2021 | Cytoki Pharma secures $45M Series A round lead by Lundbeckfonden Emerge together with Ysios, Seventure Partners and +ND Capital | 05/05/2021 Press release CYTOKI PHARMA RAISES $45 MILLION SERIES A FINANCING. Proceeds to support the development of its lead program (lipidated IL-22) through clinical proof of concept in Inflammatory Bowel Disease and explore expansion... |
| 09.07.2020 | VarmX raises €32M in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants | 08/07/2020 Press release VARMX RAISES €32 MILLION IN SERIES B FINANCING TO DEVELOP INNOVATIVE REVERSAL AGENT FOR THE TREATMENT AND PREVENTION OF SEVERE BLEEDING IN PATIENTS ON ORAL ANTICOAGULANTS. • Financing co-led by Ysios Capital and ... |
| 08.07.2020 | Ysios Capital lidera una inversión de €32M en VarmX | 08/08/2020 Nota de prensa YSIOS LIDERA UNA INVERSIÓN DE €32 MILLONES EN VARMX. – VarmX (Leiden,Países Bajos), está desarrollando un fármaco innovador para el tratamiento y prevención de hemorragias graves en pacientes tratados con antico... |
| 02.04.2019 | Aura Biosciences cierra una ronda Serie D de $40M liderada por Medicxi, acuden Ysios, Advent Life, Aris Bioscience, Chiesi, ColumbusVP y Lundbeckfonden | 02/04/2019 Nota de prensa AURA BIOSCIENCES CIERRA UNA RONDA SERIE D DE $40 MILLONES LIDERADA POR MEDICXI, ACUDEN YSIOS CAPITAL, ADVENT LIFE SCIENCES, ARIS BIOSCIENCE, CHIESI, COLUMBUSVP Y LUNDBECKFONDEN. Aura Biosciences, a leader in the... |
| 03.04.2017 | Cydan Development Announces the Acquisition of Its First Rare Disease Spin-out, Vtesse, Inc. by Sucampo Pharmaceuticals, Inc. | Link to Release Cambridge, Mass., April 3, 2017 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, today announces that Vtesse, Inc., ... |
Show more